Aurobindo Pharma Ltd

NSE: AUROPHARMA · BSE: 524804 · Pharmaceuticals & Biotechnology · 10 announcements

Share price: ₹1,712.00
Market cap: ₹99,433 Cr
Revenue (annual): ₹33,653 Cr
Net profit (annual): ₹3,505 Cr
P/E (TTM): 25.2×Sector 50.4×
Promoter holding: 51.88%+0.06% QoQ
FII holding: 16.38%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Earnings Call 4 Financial Results 2 Regulatory Approval 1 Merger & Restructuring 1 Business Update 1 Acquisition 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

1 announcement with these filters

15 Sep 2026 13:03 IST NSE

Regulatory ApprovalAlfa Alert

Aurobindo Pharma Regulatory Approval

Aurobindo Pharma received USFDA final approval for its first MDI product, Beclomethasone Dipropionate HFA Inhalation Aerosol. The US market for this segment is estimated at US$301 million.

Read the story on ALFA News Read the filing ↗